UTHR · UNITED THERAPEUTICS Corp
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| 2026 ASR agreements repurchase amount | $1.5B | March 2026 | — |
| Adcirca net product sales | $6.7M | Three Months Ended June 30, 2026 | +3.1% |
|
|
|||
| Cost of sales (excluding share-based compensation) non-GAAP | $98.5M | Three Months Ended June 30, 2026 | — |
| Effective income tax rate | 11% | Three Months Ended June 30, 2026 | — |
| External research and development | $71.2M | Three Months Ended June 30, 2026 | — |
| General and administrative expense (excluding impairment of PP&E) non-GAAP | $137.9M | Three Months Ended June 30, 2026 | — |
| Interest income | $31.5M | Three Months Ended June 30, 2026 | — |
| Orenitram net product sales | $125.7M | Three Months Ended June 30, 2026 | +1.5% |
|
|
|||
| Other income, net | $13.3M | Three Months Ended June 30, 2026 | — |
| Other net product sales | $6.8M | Three Months Ended June 30, 2026 | +23.6% |
|
|
|||
| Remodulin net product sales | $126.3M | Three Months Ended June 30, 2026 | -6.2% |
|
|
|||
| ROW total revenues | $49.7M | Three Months Ended June 30, 2026 | — |
| Sales and marketing expense | $37.3M | Three Months Ended June 30, 2026 | — |
| Total share-based compensation expense | $43.4M | Three Months Ended June 30, 2026 | — |
| Total Tyvaso revenues | $452.6M | second quarter 2026 | -3.6% |
|
|
|||
| Tyvaso DPI net product sales | $326.6M | Three Months Ended June 30, 2026 | +3.6% |
|
|
|||
| U.S. total revenues | $733.6M | Three Months Ended June 30, 2026 | — |
| Unituxin net product sales | $65.2M | Three Months Ended June 30, 2026 | +11.6% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
UTHR
this stock
UNITED THERAPEUTICS Corp
|
$21.43B | +2.6% | +2.4% | 17.9 | 5.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.59B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| UTHR | -7.3% | -6.7% | +5.3% | -3.5% | +2.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -7.7% | -11.2% | -8.5% | -7.4% | -11.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.